JUBLPHARMAJubilant Pharmova Limited
Convert to ideaPharmaceuticals & Biotechnology · Pharmaceuticals · ICRA: AA+ (Stable) · India Ratings: AA+ (Stable)
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeDown 1.2 this quarter.
Momentum from moving averages, Supertrend and RSI.
3 forensic issues found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
3 found · risk watch
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹2370 Cr | ₹31 Cr | 4.46% | 1.31% | ₹1.97 | 2.1x |
| Q1 FY2027 | ₹2229 Cr | ₹56 Cr | 5.41% | 2.53% | ₹3.57 | 2.6x |
| Q4 FY2026 | ₹2290 Cr | ₹119 Cr | 9.72% | 5.21% | ₹7.55 | 4.1x |
| Q3 FY2026 | ₹2123 Cr | ₹56 Cr | 7.95% | 2.63% | ₹3.52 | 2.7x |
| Q2 FY2026 | ₹1966 Cr | ₹120 Cr | 12.03% | 6.10% | ₹7.59 | 4.8x |
| Q1 FY2026 | ₹1901 Cr | ₹103 Cr | 10.08% | 5.39% | ₹6.49 | 4.2x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Pharmaceuticals
Compare with peers →Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment offers drug discovery services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. The company serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.